Article
A Novel CREBBP/p300 Activator, YF2, Enhances Cytotoxic and Immune-Mediated Responses in B-Cell Lymphoma
2025-03-17
Abstract excerpt
Germinal center B-cell lymphomas frequently exhibit monoallelic loss-of-function mutations in the histone acetyltransferases CREBBP and p300, which contribute to lymphoma development, disrupt normal germinal center biology, and promote immune evasion. This study evaluates YF2, a histone acetyltransferase activator that increases CREBBP/p300 activity, as a potential therapeutic approach for B-cell lymphoma. YF2 bin...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- fb44d554-17f3-522e-aa1c-c9c29ece0e01
- DOI
- 10.1101/2025.03.13.642871
